glp-1 ileus class action in louisiana Receptor Agonists and Risk of Paralytic Ileus: A drug-target Mendelian Randomization Study louisiana semaglutide bowel obstruction lawsuit – semaglutide pancreatitis class action in

LPI, 1314)

Metabolic syndrome, characterized by a group of cardiovascular risk factors, including insulin resistance, high blood pressure, high blood glucose levels, low HDL cholesterol levels, high triglyceride levels, and abdominal obesity, is associated with increased cholesterol secretion and gallstone formation (Shabanzadeh, Skaaby, Sorensen, Eugen-Olsen 2017

Semaglutide is one of the most widely prescribed GLP-1 medications for chronic weight management

(PubMed) Yaworsky K, Somwar R, Ramlal T, Tritschler HJ, Klip A

Not intended for public marketing or promotion Only

Typically, GLP-1 receptor agonists are recommended for individuals with a BMI of 30 kg/m or higher, classified as obesity, or for those with a BMI of at least 27 kg/m who also have obesity-related health conditions such as hypertension, type 2 diabetes , or high cholesterol